代谢功能障碍相关脂肪性肝病干预后cT1变化:系统综述与Meta分析
该系统综述与Meta分析纳入16项研究共1134例代谢功能障碍相关脂肪性肝病患者,评估干预后肝脏校正T1(cT1)的变化。结果显示cT1平均变化为-57 ms(95%CI -62至-52 ms),中位随访17周;成纤维细胞生长因子类似物、胰高血糖素样肽-1受体激动剂和法尼醇X受体激动剂分别使cT1平均降低79 ms、68 ms和62 ms,而安慰剂组变化为0 ms(95%CI -8至8 ms)。作者认为证据支持治疗可显著降低cT1。
要点
- 干预后cT1平均降低57 ms(95%CI -62至-52 ms),中位随访17周。
- 成纤维细胞生长因子类似物、GLP-1受体激动剂和FXR激动剂分别降低cT1 79 ms、68 ms和62 ms。
- 安慰剂组cT1平均变化为0 ms(95%CI -8至8 ms)。
核心结论
- 现有证据支持与安慰剂组微小变化相比,治疗可显著降低cT1。
- 研究结果可为在研疗法的研究设计提供参考,并支持在临床试验和临床实践中监测代谢功能障碍相关肝病患者的治疗反应。
研究设计与样本
- 系统综述与Meta分析,检索Cochrane Library、PubMed Central和MEDLINE从2014年至2024年9月的研究。
- 共纳入16项研究(N=1134例个体),包括13项随机对照试验(n=1077)和3项前瞻性饮食、生活方式及减重手术研究(n=57)。
- 两位作者独立筛选记录、评估偏倚风险并提取数据,采用Meta分析探索基线与研究结束时cT1的平均变化。
主要发现
- cT1平均变化为-57 ms(95%CI -62至-52 ms),中位随访17周(四分位距12-24周)。
- 成纤维细胞生长因子类似物组cT1平均变化为-79 ms(95%CI -90至-68 ms)。
- 胰高血糖素样肽-1受体激动剂组cT1平均变化为-68 ms(95%CI -77至-58 ms)。
- 法尼醇X受体激动剂组cT1平均变化为-62 ms(95%CI -74至-49 ms)。
- 安慰剂组cT1平均变化为0 ms(95%CI -8至8 ms)。
临床怎么用
- 作者认为研究结果可为在研疗法的研究设计提供参考,并支持在临床试验和临床实践中监测代谢功能障碍相关肝病患者的治疗反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver corrected T1 (cT1), measured with multiparametric magnetic resonance imaging, offers an alternative to liver biopsy to monitor treatment response and liver disease activity. We aimed to perform a systematic evaluation of change in cT1 following a treatment intervention in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: We searched the Cochrane Library, PubMed Central, and MEDLINE from 2014 to September 2024 for studies that examined cT1 responses following intervention in metabolic dysfunction-associated liver disease. Two authors independently screened records, assessed risk of bias, and extracted data. Meta-analyses were performed to explore the mean change in cT1 between baseline and end of study. RESULTS: A total of 16 studies (N = 1134 individuals) were analyzed (13 randomized controlled trials [n = 1077]) and 3 prospective diet, lifestyle and bariatric surgery studies [n = 57]). The mean change in cT1 was -57 ms (95% confidence interval [CI], -62 to -52 ms) over a median 17 weeks (interquartile range: 12-24 weeks). By treatment type, fibroblast growth factor analogues, glucagon-like peptide-1 receptor agonists, and farnesoid X receptor agonists, cT1 had a mean change of -79 ms (95% CI, -90 to -68 ms) to -68 ms (95% CI, -77 to -58 ms) and -62 ms (95% CI, -74 to -49 ms), respectively. In contrast, the placebo arms showed a mean change in cT1 of 0 ms (95% CI, -8 to 8 ms). CONCLUSIONS: Evidence to date supports a significant treatment-induced reduction in cT1 as compared with minimal changes in the placebo group. Our findings could inform study designs for investigational therapies and support monitoring of treatment response in individuals with metabolic dysfunction-associated liver disease in clinical trials and clinical practice.
引用
- Andersson A, Loomba R, Beyer C, et al. Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2025. PMID: 40220846. doi:10.1016/j.cgh.2025.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。